Profile picture

Doctor Joakim Bo Kunkel

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
Membership: ACVC Member
Follow
Biography
MD, PhD. Background in critical care and randomised clinical trials; currently a postdoctoral researcher in the REACT programme. Research interests include inflammation, cardiovascular imaging, and translational digital health.
Logo ESC

Contributor content

Machine learning analysis of ECG changes following tocilizumab treatment in out-of-hospital cardiac arrest patients
Presentation
Machine learning analysis of ECG changes following tocilizumab treatment in out-of-hospital cardiac arrest patients
Machine learning for differentiating shock types using inflammatory markers
Presentation
Machine learning for differentiating shock types using inflammatory markers
ORBI risk score and inflammatory response in patients with acute ST-elevation myocardial infarction
Presentation
ORBI risk score and inflammatory response in patients with acute ST-elevation myocardial infarction
Cardiogenic shock due to acute right ventricular failure in ST-elevation myocardial infarction
Presentation
Cardiogenic shock due to acute right ventricular failure in ST-elevation myocardial infarction
Psychotropic medication use and mortality in patients with acute myocardial infarction complicated by cardiogenic shock
Presentation
Psychotropic medication use and mortality in patients with acute myocardial infarction complicated by cardiogenic shock
Myocardial salvage and infarct characteristics in patients with ST-elevation myocardial infarction classified by ORBI risk score
Presentation
Myocardial salvage and infarct characteristics in patients with ST-elevation myocardial infarction classified by ORBI risk score
Sex differences in acute hemodynamic response in comatose survivors of OHCA
Presentation
Sex differences in acute hemodynamic response in comatose survivors of OHCA
Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development - rationale and design of the DOBERMANN trial
Presentation
Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development - rationale and design of the DOBERMANN trial
Association between inflammatory biomarkers and 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
Presentation
Association between inflammatory biomarkers and 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
Association between inflammatory biomarkers and 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock
Presentation
Association between inflammatory biomarkers and 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock

ESC 365 is supported by